Your only mesothelioma treatments news source!
Click on each item to read full story.

 
The Mesothelioma Victims Center Adds The MD Anderson Cancer Clinic At The University Of Texas As New Resource For ...
read story
The Mesothelioma Victims Center says, "This week we have added the University Of Texas' MD Anderson Clinic to our list of resources given out to diagnosed victims of mesothelioma inquiring about information related to this rare form of malignant cancer. We are excited to provide families going through a recent diagnosis with free information on what the treatment options are as well as where to ...
 
Mesothelioma Victims Center Points To A New Spanish Study About High Dose Radiation And Urges Diagnosed Victims To ...
read story
The Mesothelioma Victims Center is pointing to a new study from Spain that indicates high dose radiation combined with radical surgery for diagnosed victims of mesothelioma added no benefit as far as lengthening the life of a victim was concerned. However, the Mesothelioma Victims Center is suggesting some new US treatments may offer better results with the qualifier being that the earlier the ...
 
Study Finds Oral Medication May Slow Mesothelioma Progression, Reports Surviving Mesothelioma
read story
Newly published research finds that a combination of oral drugs may offer an additional treatment option for mesothelioma patients who have already undergone chemotherapy. (PRWeb November 10, 2014) Read the full story at http://www.prweb.com/releases/2014/11/prweb12311937.htm
 
Study Finds Dosing Schedule Critical for Promising New Mesothelioma Treatment, Reports Surviving Mesothelioma
read story
The order in which a proposed new treatment combination is administered to mesothelioma patients appears to impact effectiveness and tumor regrowth. (PRWeb November 15, 2014) Read the full story at http://www.prweb.com/releases/2014/11/prweb12324981.htm
 
Meso Foundation Congratulates National Cancer Institute Researcher for Prestigious Award
read story
The Mesothelioma Applied Research Foundation (Meso Foundation) congratulates former Science Advisory Board member and researcher at the National Cancer Institute, Raffit Hassan, MD, for receiving the prestigious Wagner Medal at the International Mesothelioma Interest Group (iMig) meeting last week. (PRWeb October 30, 2014) Read the full story at http://www.prweb.com/releases/2014/11 ...
 
Cancer Research Foundation Announces New Board Member
read story
The Mesothelioma Applied Research Foundation (Meso Foundation) announced today that Melissa Culligan, RN, BSN, MS, a thoracic surgery nurse with extensive mesothelioma experience, has joined the organization’s Board of Directors. (PRWeb October 30, 2014) Read the full story at http://www.prweb.com/releases/2014/11/prweb12291811.htm
 
Verastem Presents Data at the 2014 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
read story
Verastem, Inc. , focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced four poster presentations at
 
Deadly Cancer Disproportionately Affects Our Veterans
read story
On Veterans Day, the Mesothelioma Applied Research Foundation (Meso Foundation) raises awareness of deadly cancer that disproportionately affects the men and women who have served in the U.S. armed forces. (PRWeb November 11, 2014) Read the full story at http://www.prweb.com/releases/2014/11/prweb12316239.htm
 
Mesothelioma Victims Center Comments on Biopsies and How CT Scans Might Not Be as Accurate as Once Thought in ...
read story
The Mesothelioma Victims Center is convinced that hundreds, possibly thousands, of US citizens lose out on compensation each and every year because they did not have the knowledge or understanding that a loved one could be sick with mesothelioma after having been unknowingly exposed to asbestos for long periods of time while in the workplace. To keep victims and family members up-to-date with ...
 
Research Foundation Sees Much Promise in Treatment of Deadly Cancer
read story
The Mesothelioma Applied Research Foundation is optimistic about results reported by AduroBioTech, Inc. of their Phase 1b clinical trial of CRs-207, a novel immunotherapy agent. (PRWeb October 31, 2014) Read the full story at http://www.prweb.com/releases/2014/11/prweb12293981.htm